Global Interleukin 17A Market Outlook and Growth Opportunities 2025

Summary

According to APO Research, the global Interleukin 17A market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Interleukin 17A is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Interleukin 17A is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Interleukin 17A market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Interleukin 17A is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Interleukin 17A market include Abeome Corporation, Affibody AB, Cell Medica Limited, Orega Biotech SAS, AbbVie Inc, Eli Lilly and Company, Merck KGaA, Novartis AG and Johnson & Johnson, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Interleukin 17A, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Interleukin 17A, also provides the sales of main regions and countries. Of the upcoming market potential for Interleukin 17A, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Interleukin 17A sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Interleukin 17A market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Interleukin 17A sales, projected growth trends, production technology, application and end-user industry.

Interleukin 17A Segment by Company

Abeome Corporation
Affibody AB
Cell Medica Limited
Orega Biotech SAS
AbbVie Inc
Eli Lilly and Company
Merck KGaA
Novartis AG
Johnson & Johnson

Interleukin 17A Segment by Type

DLX-2882
CNTO-6785
ABY-035
Others

Interleukin 17A Segment by Application

Kidney Cancer
Chronic Pain
Liver Cancer
Others

Interleukin 17A Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Interleukin 17A status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Interleukin 17A market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Interleukin 17A significant trends, drivers, influence factors in global and regions.
6. To analyze Interleukin 17A competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Interleukin 17A market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Interleukin 17A and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Interleukin 17A.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Interleukin 17A market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Interleukin 17A industry.
Chapter 3: Detailed analysis of Interleukin 17A manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Interleukin 17A in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Interleukin 17A in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Interleukin 17A Sales Value (2020-2031)
1.2.2 Global Interleukin 17A Sales Volume (2020-2031)
1.2.3 Global Interleukin 17A Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Interleukin 17A Market Dynamics
2.1 Interleukin 17A Industry Trends
2.2 Interleukin 17A Industry Drivers
2.3 Interleukin 17A Industry Opportunities and Challenges
2.4 Interleukin 17A Industry Restraints
3 Interleukin 17A Market by Company
3.1 Global Interleukin 17A Company Revenue Ranking in 2024
3.2 Global Interleukin 17A Revenue by Company (2020-2025)
3.3 Global Interleukin 17A Sales Volume by Company (2020-2025)
3.4 Global Interleukin 17A Average Price by Company (2020-2025)
3.5 Global Interleukin 17A Company Ranking (2023-2025)
3.6 Global Interleukin 17A Company Manufacturing Base and Headquarters
3.7 Global Interleukin 17A Company Product Type and Application
3.8 Global Interleukin 17A Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Interleukin 17A Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Interleukin 17A Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Interleukin 17A Market by Type
4.1 Interleukin 17A Type Introduction
4.1.1 DLX-2882
4.1.2 CNTO-6785
4.1.3 ABY-035
4.1.4 Others
4.2 Global Interleukin 17A Sales Volume by Type
4.2.1 Global Interleukin 17A Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Interleukin 17A Sales Volume by Type (2020-2031)
4.2.3 Global Interleukin 17A Sales Volume Share by Type (2020-2031)
4.3 Global Interleukin 17A Sales Value by Type
4.3.1 Global Interleukin 17A Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Interleukin 17A Sales Value by Type (2020-2031)
4.3.3 Global Interleukin 17A Sales Value Share by Type (2020-2031)
5 Interleukin 17A Market by Application
5.1 Interleukin 17A Application Introduction
5.1.1 Kidney Cancer
5.1.2 Chronic Pain
5.1.3 Liver Cancer
5.1.4 Others
5.2 Global Interleukin 17A Sales Volume by Application
5.2.1 Global Interleukin 17A Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Interleukin 17A Sales Volume by Application (2020-2031)
5.2.3 Global Interleukin 17A Sales Volume Share by Application (2020-2031)
5.3 Global Interleukin 17A Sales Value by Application
5.3.1 Global Interleukin 17A Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Interleukin 17A Sales Value by Application (2020-2031)
5.3.3 Global Interleukin 17A Sales Value Share by Application (2020-2031)
6 Interleukin 17A Regional Sales and Value Analysis
6.1 Global Interleukin 17A Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Interleukin 17A Sales by Region (2020-2031)
6.2.1 Global Interleukin 17A Sales by Region: 2020-2025
6.2.2 Global Interleukin 17A Sales by Region (2026-2031)
6.3 Global Interleukin 17A Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Interleukin 17A Sales Value by Region (2020-2031)
6.4.1 Global Interleukin 17A Sales Value by Region: 2020-2025
6.4.2 Global Interleukin 17A Sales Value by Region (2026-2031)
6.5 Global Interleukin 17A Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Interleukin 17A Sales Value (2020-2031)
6.6.2 North America Interleukin 17A Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Interleukin 17A Sales Value (2020-2031)
6.7.2 Europe Interleukin 17A Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Interleukin 17A Sales Value (2020-2031)
6.8.2 Asia-Pacific Interleukin 17A Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Interleukin 17A Sales Value (2020-2031)
6.9.2 South America Interleukin 17A Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Interleukin 17A Sales Value (2020-2031)
6.10.2 Middle East & Africa Interleukin 17A Sales Value Share by Country, 2024 VS 2031
7 Interleukin 17A Country-level Sales and Value Analysis
7.1 Global Interleukin 17A Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Interleukin 17A Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Interleukin 17A Sales by Country (2020-2031)
7.3.1 Global Interleukin 17A Sales by Country (2020-2025)
7.3.2 Global Interleukin 17A Sales by Country (2026-2031)
7.4 Global Interleukin 17A Sales Value by Country (2020-2031)
7.4.1 Global Interleukin 17A Sales Value by Country (2020-2025)
7.4.2 Global Interleukin 17A Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Interleukin 17A Sales Value Growth Rate (2020-2031)
7.5.2 USA Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Interleukin 17A Sales Value Growth Rate (2020-2031)
7.6.2 Canada Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Interleukin 17A Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Interleukin 17A Sales Value Growth Rate (2020-2031)
7.8.2 Germany Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Interleukin 17A Sales Value Growth Rate (2020-2031)
7.9.2 France Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.9.3 France Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Interleukin 17A Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Interleukin 17A Sales Value Growth Rate (2020-2031)
7.11.2 Italy Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Interleukin 17A Sales Value Growth Rate (2020-2031)
7.12.2 Spain Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Interleukin 17A Sales Value Growth Rate (2020-2031)
7.13.2 Russia Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Interleukin 17A Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Interleukin 17A Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Interleukin 17A Sales Value Growth Rate (2020-2031)
7.16.2 China Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.16.3 China Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Interleukin 17A Sales Value Growth Rate (2020-2031)
7.17.2 Japan Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Interleukin 17A Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Interleukin 17A Sales Value Growth Rate (2020-2031)
7.19.2 India Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.19.3 India Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Interleukin 17A Sales Value Growth Rate (2020-2031)
7.20.2 Australia Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Interleukin 17A Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Interleukin 17A Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Interleukin 17A Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Interleukin 17A Sales Value Growth Rate (2020-2031)
7.24.2 Chile Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Interleukin 17A Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Interleukin 17A Sales Value Growth Rate (2020-2031)
7.26.2 Peru Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Interleukin 17A Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Interleukin 17A Sales Value Growth Rate (2020-2031)
7.28.2 Israel Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Interleukin 17A Sales Value Growth Rate (2020-2031)
7.29.2 UAE Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Interleukin 17A Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Interleukin 17A Sales Value Growth Rate (2020-2031)
7.31.2 Iran Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Interleukin 17A Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Interleukin 17A Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Interleukin 17A Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Interleukin 17A Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Abeome Corporation
8.1.1 Abeome Corporation Comapny Information
8.1.2 Abeome Corporation Business Overview
8.1.3 Abeome Corporation Interleukin 17A Sales, Value and Gross Margin (2020-2025)
8.1.4 Abeome Corporation Interleukin 17A Product Portfolio
8.1.5 Abeome Corporation Recent Developments
8.2 Affibody AB
8.2.1 Affibody AB Comapny Information
8.2.2 Affibody AB Business Overview
8.2.3 Affibody AB Interleukin 17A Sales, Value and Gross Margin (2020-2025)
8.2.4 Affibody AB Interleukin 17A Product Portfolio
8.2.5 Affibody AB Recent Developments
8.3 Cell Medica Limited
8.3.1 Cell Medica Limited Comapny Information
8.3.2 Cell Medica Limited Business Overview
8.3.3 Cell Medica Limited Interleukin 17A Sales, Value and Gross Margin (2020-2025)
8.3.4 Cell Medica Limited Interleukin 17A Product Portfolio
8.3.5 Cell Medica Limited Recent Developments
8.4 Orega Biotech SAS
8.4.1 Orega Biotech SAS Comapny Information
8.4.2 Orega Biotech SAS Business Overview
8.4.3 Orega Biotech SAS Interleukin 17A Sales, Value and Gross Margin (2020-2025)
8.4.4 Orega Biotech SAS Interleukin 17A Product Portfolio
8.4.5 Orega Biotech SAS Recent Developments
8.5 AbbVie Inc
8.5.1 AbbVie Inc Comapny Information
8.5.2 AbbVie Inc Business Overview
8.5.3 AbbVie Inc Interleukin 17A Sales, Value and Gross Margin (2020-2025)
8.5.4 AbbVie Inc Interleukin 17A Product Portfolio
8.5.5 AbbVie Inc Recent Developments
8.6 Eli Lilly and Company
8.6.1 Eli Lilly and Company Comapny Information
8.6.2 Eli Lilly and Company Business Overview
8.6.3 Eli Lilly and Company Interleukin 17A Sales, Value and Gross Margin (2020-2025)
8.6.4 Eli Lilly and Company Interleukin 17A Product Portfolio
8.6.5 Eli Lilly and Company Recent Developments
8.7 Merck KGaA
8.7.1 Merck KGaA Comapny Information
8.7.2 Merck KGaA Business Overview
8.7.3 Merck KGaA Interleukin 17A Sales, Value and Gross Margin (2020-2025)
8.7.4 Merck KGaA Interleukin 17A Product Portfolio
8.7.5 Merck KGaA Recent Developments
8.8 Novartis AG
8.8.1 Novartis AG Comapny Information
8.8.2 Novartis AG Business Overview
8.8.3 Novartis AG Interleukin 17A Sales, Value and Gross Margin (2020-2025)
8.8.4 Novartis AG Interleukin 17A Product Portfolio
8.8.5 Novartis AG Recent Developments
8.9 Johnson & Johnson
8.9.1 Johnson & Johnson Comapny Information
8.9.2 Johnson & Johnson Business Overview
8.9.3 Johnson & Johnson Interleukin 17A Sales, Value and Gross Margin (2020-2025)
8.9.4 Johnson & Johnson Interleukin 17A Product Portfolio
8.9.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Interleukin 17A Value Chain Analysis
9.1.1 Interleukin 17A Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Interleukin 17A Sales Mode & Process
9.2 Interleukin 17A Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Interleukin 17A Distributors
9.2.3 Interleukin 17A Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings